For CliniciansEvidence-Based

One Product.
Complete CIWA Coverage.

Rebound Vitamins replaces Thiamine, Magnesium, and multivitamins in alcohol withdrawal protocols — consolidating four standard supplementation orders into a single, clinically complete product designed for CIWA-Ar care.

4 → 1
Orders consolidated
6 wks
Full recovery protocol
100mg
Thiamine per tablet
Evidence-Based Formulation

Why Each Ingredient Is Included

Every component of Rebound Vitamins addresses a documented nutritional deficiency common in patients with alcohol use disorder undergoing CIWA-Ar monitored withdrawal.

Thiamine (Vitamin B1) — 100mg

Thiamine deficiency is present in up to 80% of patients with alcohol use disorder. Rebound provides 100mg per tablet — the standard prophylactic dose — to prevent Wernicke's encephalopathy during withdrawal.

1 Thomson AD et al. Alcohol Alcohol. 2002;37(6):513–521.

Folate (Vitamin B9) — 0.4mg

Chronic alcohol use impairs folate absorption and increases urinary excretion. Folate deficiency contributes to macrocytic anemia and neurological dysfunction. Rebound provides 0.4mg per tablet for daily repletion.

2 Halsted CH et al. Alcohol. 2002;27(3):169–172.

Magnesium

Hypomagnesemia is common in alcohol withdrawal and lowers the seizure threshold. Oral magnesium supplementation supports benzodiazepine efficacy and reduces neuromuscular excitability throughout the withdrawal period.

3 Elisaf M et al. J Trace Elem Med Biol. 1995;9(4):210–214.

Full B-Complex + Vitamins C, D, E, Zinc

Patients with alcohol use disorder are broadly malnourished. Rebound includes a complete micronutrient profile to address the full spectrum of nutritional deficiencies common in this population — not just the three protocol-required supplements.

4 Leevy CM, Baker H. Am J Clin Nutr. 1968;21(11):1325–1328.

Step-by-Step Integration

How to Integrate Rebound Into Your Protocol

Rebound Vitamins is designed to slot directly into the UCSF symptom-triggered CIWA-Ar protocol. Follow these four steps from admission through the 6-week recovery period.

Symptom-triggered protocol reference: Saitz R et al. JAMA. 1994;272(7):519–523.6 Daeppen JB et al. Arch Intern Med. 2002;162(10):1117–1121.7

1

Initiate at Admission

Order Rebound Vitamins 1 tablet PO twice daily at admission, as soon as the patient is tolerating oral intake. This replaces the Thiamine, Folic Acid, and oral Magnesium orders from your standard CIWA supplementation set.

If PO not tolerated or Wernicke's encephalopathy suspected: give IV Thiamine 500 mg TID × 3 days (Pabrinex or equivalent) before any glucose-containing fluids. Do NOT use 100 mg IV — this dose is insufficient for treatment of suspected Wernicke's encephalopathy (Thomson et al., 2002; EFNS Guidelines, 2010).

2

Continue BID Through Day 5

Maintain 1 tablet twice daily throughout the active withdrawal period (Days 1–5). This aligns with the UCSF symptom-triggered protocol monitoring window and the period of highest nutritional demand.

Continue alongside lorazepam dosing per CIWA-Ar score. Rebound does not interact with benzodiazepines.

3

Transition to Once Daily — Day 6

Beginning Day 6, reduce to 1 tablet once daily. Continue for 6 weeks to support ongoing nutritional recovery, liver function restoration, and neurological repair during early sobriety.

Coordinate with outpatient follow-up. Rebound can be prescribed at discharge for the maintenance phase.

4

Discharge & Outpatient Continuation

Prescribe or recommend Rebound Vitamins at discharge for the 6-week maintenance period. Coordinate with addiction medicine, primary care, or outpatient follow-up to ensure continuity of nutritional support.

Patients can order directly at reboundvitamins.com or through their outpatient provider.

Prescribing Summary

Indication

All patients undergoing CIWA-Ar monitored alcohol withdrawal who are tolerating oral intake.

Active Withdrawal (Days 1–5)

1 tablet twice daily (BID)

With water or food. Initiate at admission.

Recovery Phase (Day 6 – 6 Weeks)

1 tablet once daily

Continue through full 6-week recovery period.

Simplified Order Set

Standard Orders vs. Rebound Vitamins

Rebound consolidates four standard CIWA supplementation orders into a single product — without removing any clinically required component.

Standard CIWA Order
Rebound Vitamins
Thiamine 100mg PO/IM/IV
✓ Included — 100mg per tablet
Folic Acid 0.4mg PO daily
✓ Included — 0.4mg per tablet
Magnesium (oral) as indicated
✓ Included — elemental Mg per tablet
Multivitamin PO daily
✓ Included — full B-complex + C, D, E, Zinc
4 separate orders to manage
1 product. Complete coverage.

Fewer Orders

Reduce medication reconciliation burden and order entry errors with a single supplementation product.

No Gaps in Coverage

All four standard CIWA supplementation components are present — nothing is omitted or reduced.

Better Patient Adherence

One tablet twice daily is simpler for patients to follow than four separate supplements — especially during active withdrawal.

Emergency Department Physician Message

The Financial & Clinical Impact of Alcohol-Related Hospital Readmissions

Alcohol-related hospital readmissions represent a significant clinical and financial burden on American healthcare. Patients with chronic alcohol use frequently return to emergency departments with alcohol withdrawal, dehydration, electrolyte abnormalities, malnutrition, recurrent intoxication, and complications associated with thiamine deficiency.

For emergency physicians, the challenge extends beyond treating the immediate episode. It includes identifying preventable complications, improving discharge planning, and reducing the cycle of repeated emergency visits and hospital admissions.

Rebound Vitamins can be positioned as part of a comprehensive, physician-directed nutritional discharge strategy — not as a replacement for alcohol withdrawal treatment, prescribed thiamine, or evidence-based alcohol use disorder care.

Published 30-Day Alcohol-Related Readmission Rate
18.9%

Approximately 1 in 5 alcohol-related hospitalizations resulted in at least one readmission within 30 days.

2014 U.S. hospital discharge data; 285,767 alcohol-related index hospitalizations. Published 2019 via PubMed. A separate national study (2010–2015) found 30-day readmissions increased from 119 to 140 per 1,000 admissions while the overall hospital readmission rate declined over the same period.

Illustrative 30-Day Readmission Estimates

Based on the published 18.9% rate. Individual hospitals should calculate their own current readmission rates.

100 admissions
~19 readmissions
at the 18.9% historical rate
500 admissions
~95 readmissions
at the 18.9% historical rate
1,000 admissions
~189 readmissions
at the 18.9% historical rate

The Financial Consequences

Under the Centers for Medicare & Medicaid Services (CMS) Hospital Readmissions Reduction Program (HRRP), eligible hospitals with excess readmissions can experience Medicare payment reductions of up to 3%. The reduction applies to Medicare fee-for-service base operating DRG payments across the hospital's applicable discharges — not simply to the individual readmission.

HRRP Reduction
Annual Payment Reduction*
0.5%
$500,000
1.0%
$1,000,000
2.0%
$2,000,000
3.0%
$3,000,000

*Illustrative financial calculations for a hospital with $100 million in applicable Medicare payments. Not actual hospital penalties. Alcohol use disorder itself is not a standalone HRRP target condition. An unplanned alcohol-related readmission following a qualifying index hospitalization may count toward the applicable measure.

Critical Distinction

The HRRP specifically measures readmissions associated with selected conditions and procedures, including heart failure, pneumonia, COPD, heart attack, coronary artery bypass surgery, and hip or knee replacement. An alcohol-related readmission is not automatically an HRRP-penalized event. However, an unplanned alcohol-related readmission following a qualifying index hospitalization may count toward the applicable measure.

The Rebound Opportunity

Patients with chronic alcohol use are vulnerable to nutritional deficiencies, including deficiencies involving thiamine, folate, and magnesium. These deficiencies deserve particular attention during emergency treatment, hospitalization, and discharge planning.

W. Peoples Rebound™ Micronutrient System provides a combination of vitamins and magnesium designed to support nutritional supplementation in patients with a history of chronic alcohol use. Rebound may be considered as an adjunct to an individualized discharge plan that includes appropriate thiamine treatment, correction of identified deficiencies, alcohol use disorder treatment, medication management, and follow-up care.

Address the nutritional component of recovery before patients leave the hospital
A more comprehensive discharge process may help address unmet patient needs
Nutritional support, alongside established treatment, may contribute to improved outcomes
Fewer avoidable returns — clinically important and financially relevant

W. Peoples Rebound™ — Supporting Nutritional Recovery Beyond Hospital Discharge. reboundvitamins.com

Clinical Recognition

12 Signs of High-Functioning Alcoholism

High-functioning alcohol use disorder is frequently missed in clinical settings because patients maintain professional and social performance. These 12 signs help clinicians identify patients who may be underreporting or unaware of the severity of their dependence.

High-functioning AUD patients often present without obvious social consequences, making AUDIT-C and CAGE screening tools essential adjuncts to clinical observation.9,10 Nutritional deficiencies (Thiamine, Folate, Magnesium) accumulate silently in this population before acute withdrawal occurs.1,2,3

BehavioralSocialNeurologicalPhysiologicalNutritionalLegal/Financial
01
Behavioral

Drinks to Relax or Cope

Uses alcohol consistently to manage stress, anxiety, or emotional discomfort. May describe drinking as "necessary" to unwind — a hallmark of psychological dependence.

02
Social

Maintains High Functioning at Work

Holds a professional job, meets deadlines, and appears high-performing. Colleagues rarely suspect a problem — making clinical identification significantly harder.

03
Behavioral

Denies or Minimizes Consumption

Consistently underreports quantity and frequency. May rationalize by comparing to peers ("I drink less than my coworkers") or citing professional success as evidence of no problem.

04
Behavioral

Drinks Alone or in Secret

Conceals drinking from family, friends, or colleagues. May keep alcohol in the car, office, or hidden at home to avoid scrutiny.

05
Neurological

Blackouts Without Apparent Intoxication

Experiences memory gaps during drinking episodes but does not appear visibly drunk. High tolerance masks severity from observers — and from the patient themselves.

06
Physiological

Increased Tolerance Over Time

Requires progressively more alcohol to achieve the same effect. May pride themselves on their ability to "hold their liquor" — a clinical warning sign, not a strength.

07
Behavioral

Jokes About Drinking

Uses humor to normalize or deflect concern. Frequent self-deprecating jokes about drinking may signal awareness of a problem without willingness to address it.

08
Behavioral

Rigid Drinking Rituals

Drinks at specific times (e.g., exactly 5pm, always with dinner). Becomes irritable or anxious when rituals are disrupted — a sign of psychological dependence.

09
Nutritional

Neglects Nutrition

Skips meals, substitutes alcohol for food, or eats poorly. This pattern accelerates Thiamine, Folate, and Magnesium depletion — the exact deficiencies Rebound addresses.

10
Social

Relationship and Family Strain

Close relationships are affected even when professional life appears intact. Partners and family often recognize the problem before colleagues or clinicians.

11
Legal/Financial

Legal or Financial Issues

May have a history of DUI, financial mismanagement, or impulsive decisions made while drinking — often minimized or attributed to other causes during clinical intake.

12
Behavioral

Failed Attempts to Cut Back

Has tried to reduce or stop drinking independently, without success. May have set rules ("only on weekends") that are repeatedly broken — a hallmark of alcohol use disorder.

Clinical Note: Patients presenting with 3 or more of these signs warrant formal AUD screening (AUDIT-C, CAGE) and nutritional assessment. Even without acute withdrawal, chronic alcohol use depletes Thiamine, Folate, and Magnesium — making prophylactic supplementation with Rebound Vitamins clinically appropriate at the time of identification, not only at withdrawal.

AUDIT-C sensitivity 73–86% for AUD in primary care settings. Bush K et al. Arch Intern Med. 1998;158(16):1789–1795.9

Emergency Management

Delirium Tremens & Seizure Treatment Protocols

Delirium tremens (DTs) carries a mortality rate of up to 5–15% if untreated. Alcohol withdrawal seizures occur in 5–10% of patients, typically within 6–48 hours of last drink. The following protocols reflect current evidence-based practice for refractory and severe cases.

ICU-Level Care Required

Patients with CIWA-Ar ≥ 20, active seizures, or signs of DTs (autonomic instability, hallucinations, altered sensorium) require continuous monitoring, IV access, airway management readiness, and ICU or step-down admission. All agents below should be administered by trained clinical staff with resuscitation equipment available.

1First-Line: Benzodiazepines

Lorazepam (Ativan)
IV / IM
Dose: 2–4 mg IV q5–15 min PRN
Max: No fixed ceiling in refractory DTs — titrate to effect
Preferred first-line agent. Short-acting, predictable kinetics, minimal active metabolites. Use IV for fastest onset in active seizure. IM acceptable if IV access unavailable.
Diazepam (Valium)
IV / PO
Dose: 5–10 mg IV q5–10 min; or 10–20 mg PO q1–2h
Max: Up to 100+ mg in first 3–4 hours for severe DTs
Long-acting with active metabolites — provides "self-tapering" effect. Preferred by some centers for DT prevention. Avoid in hepatic failure due to accumulation.

2Second-Line / Adjunct: Phenobarbital

Phenobarbital
IV / IM / PO
Loading Dose
10–15 mg/kg IV at ≤ 60 mg/min (max 1,000 mg per dose)
Maintenance
30–120 mg PO/IV q6–8h; taper over 5–7 days
Adjunct Dosing
130–260 mg IV q15–20 min alongside benzodiazepines for refractory DTs
Clinical Rationale & Considerations
MechanismGABA-A positive allosteric modulator (barbiturate site) — distinct from benzodiazepine binding site. Additive effect when combined with BZDs, making it highly effective for refractory DTs.
EvidenceMultiple RCTs and meta-analyses support phenobarbital monotherapy or adjunct use for AWS. Associated with reduced ICU LOS and lower total BZD requirements (Tidwell et al., 2018; Nisavic et al., 2019).
AdvantagesLong half-life (80–120 hrs) provides smooth self-taper. No active metabolite accumulation concern. Effective anticonvulsant for withdrawal seizures.
CautionsRespiratory depression risk — especially with concurrent BZDs. Monitor SpO₂ continuously. Avoid in severe hepatic impairment. Have flumazenil and airway equipment at bedside.

3Refractory DTs / Super-Refractory Seizures: Midazolam & Ketamine

Midazolam
IV Infusion / IM
Bolus
2–5 mg IV q5 min until sedation; or 5–10 mg IM for acute seizure
Continuous Infusion
0.05–0.4 mg/kg/hr IV; titrate to RASS –2 to –3 for refractory DTs
Indication
Refractory DTs unresponsive to high-dose BZDs ± phenobarbital. Requires intubation if infusion > 0.1 mg/kg/hr sustained.
Key Advantage
Rapid onset (1–3 min IV), titratable, water-soluble — no propylene glycol toxicity risk unlike lorazepam infusions.
Ketamine
IV Infusion / IM
Sub-dissociative Dose
0.1–0.3 mg/kg/hr IV infusion as adjunct to BZDs — reduces BZD requirements
Dissociative / Seizure Abort
1–2 mg/kg IV bolus or 4–5 mg/kg IM for status epilepticus refractory to BZDs
Mechanism
NMDA receptor antagonist — addresses glutamate excitotoxicity central to AWS pathophysiology. Complements GABA-ergic agents.
Emerging Evidence
Retrospective studies show ketamine adjunct reduces total BZD dose by 30–50% in severe AWS (Pizon et al., 2020; Shah et al., 2018). Preserves airway reflexes at sub-dissociative doses.

4Last Resort (Intubated Patients): Propofol

Dose: 5–80 mcg/kg/min IV infusion; titrate to RASS –3 to –5
Indication: Super-refractory DTs or status epilepticus in intubated, mechanically ventilated patients only
Mechanism: GABA-A potentiation + NMDA antagonism. Rapid onset and offset allows neurological assessment.
Monitor: Propofol infusion syndrome (PRIS) risk with doses > 4 mg/kg/hr > 48 hrs — check triglycerides, lactate, CK q24h
Caution: Not appropriate for non-intubated patients. Requires continuous EEG monitoring in refractory status epilepticus.

Treatment Escalation Algorithm

1
Step 1
CIWA-Ar ≥ 10 or First Seizure
Lorazepam 2–4 mg IV/IM q15 min PRN + REBOUND Vitamins BID (if PO tolerated) + IV Thiamine 500 mg TID × 3 days if Wernicke's suspected or PO not tolerated. Give Thiamine BEFORE any dextrose.
2
Step 2
Inadequate Response to BZDs (> 40 mg lorazepam in 4 hrs)
Add Phenobarbital 10 mg/kg IV load. Continue BZD PRN. Transfer to ICU. Continuous monitoring.
3
Step 3
Refractory DTs / Recurrent Seizures
Add Ketamine 0.1–0.3 mg/kg/hr infusion OR Midazolam infusion 0.05–0.2 mg/kg/hr. Prepare for intubation.
4
Step 4
Super-Refractory / Intubated
Propofol infusion 5–80 mcg/kg/min. Continuous EEG. Neurology consult. Consider Dexmedetomidine adjunct for autonomic stabilization.
Nutritional Support in DTs — REBOUND Vitamins Role

All patients with DTs or withdrawal seizures should receive aggressive nutritional repletion. If the patient can take oral medications, continue REBOUND Vitamins 1 tablet BID throughout the acute phase. If PO is not tolerated (intubated or altered sensorium), substitute with the IV protocol below.

Wernicke's Encephalopathy Warning: The classic triad (ophthalmoplegia, ataxia, confusion) is present in only 16% of cases at autopsy (Harper et al., 1986). Treat empirically with high-dose IV Thiamine in any patient with AUD + altered mental status, nutritional deficiency, or prior to glucose administration. 100 mg IV is a prophylactic dose only — it is NOT adequate treatment for suspected Wernicke's.
Thiamine (B1)
500 mg IV TID × 3 days
Then 250 mg IV daily × 5 days, then oral REBOUND
Pabrinex 2 pairs IV TID. Give BEFORE any dextrose. 100 mg IV = prophylaxis only — use 500 mg TID for suspected Wernicke's (EFNS 2010; Thomson et al., 2002).
Magnesium Sulfate
2–4 g IV over 4–6 hrs
Repeat q6–8h PRN; target Mg ≥ 1.0 mmol/L
Hypomagnesemia lowers seizure threshold and impairs Thiamine utilization. Correct aggressively in DTs.
Folic Acid
1 mg IV/PO daily
Continue throughout admission
Resume REBOUND Vitamins (400 mcg Folic Acid per tablet) as soon as PO is tolerated.
Reimbursement Guide

Medicaid Billing for Alcohol Rehabilitation

Medicaid covers a broad spectrum of alcohol use disorder (AUD) treatment services. Understanding the correct billing codes maximizes reimbursement and ensures your facility captures every dollar it has earned — while supporting patients who may have no other coverage.

Financial Opportunity
$3,000–$18,000+

Estimated Medicaid reimbursement range per patient for a complete inpatient alcohol detox and rehabilitation episode, depending on length of stay, level of care, and state Medicaid plan. Proper code selection is the difference between partial and full capture.

Private Practice Billing & Reimbursement Guide
Complete E&M, MAT, SBIRT, and telehealth codes for office-based AUD management — with documentation requirements, payer-specific guidance, and Rebound Vitamins integration notes.
View Billing Guide

Key Medicaid Billing Codes — Alcohol Rehabilitation

Code
Type
Description
Est. Medicaid Rate
H0010
HCPCS — Detox
Alcohol and/or drug services; subacute detoxification (residential addiction program)
$150–$350/day
H0011
HCPCS — Detox
Alcohol and/or drug services; acute detoxification (residential addiction program)
$350–$800/day
H0012
HCPCS — Rehab
Alcohol and/or drug services; subacute rehabilitation (residential addiction program)
$150–$300/day
H0013
HCPCS — Rehab
Alcohol and/or drug services; acute rehabilitation (residential addiction program)
$300–$700/day
H0015
HCPCS — Intensive
Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day)
$100–$250/day
H0020
HCPCS — MAT
Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)
$12–$30/day
H2034
HCPCS — MAT
Alcohol and/or drug abuse halfway house services, per diem
$60–$150/day
99213
E&M — Office Visit
Office or outpatient visit, established patient, moderate complexity — used for medication management (naltrexone, acamprosate)
$75–$130
99214
E&M — Office Visit
Office or outpatient visit, established patient, moderate-high complexity — AUD with co-occurring conditions
$110–$175
99408
Screening
Alcohol and/or substance (other than tobacco) abuse structured screening (e.g., AUDIT, DAST), 15–30 minutes
$30–$60
99409
Screening
Alcohol and/or substance abuse structured screening, greater than 30 minutes
$55–$100
G2067
MAT — Buprenorphine
Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy
$160–$300/week
T1006
Case Management
Alcohol and/or substance abuse services, case management, per 15 minutes
$15–$35/unit
90832
Psychotherapy
Psychotherapy, 30 minutes with patient — individual therapy for AUD
$50–$90
90837
Psychotherapy
Psychotherapy, 60 minutes with patient — individual therapy for AUD
$90–$160
90853
Group Therapy
Group psychotherapy (other than of a multiple-family group) — group AUD counseling
$20–$50/patient

* Rates are illustrative estimates based on national Medicaid fee schedules. Actual reimbursement varies by state Medicaid plan, managed care organization (MCO) contract, facility type, and modifier usage. Always verify with your state Medicaid agency or MCO.

Supporting ICD-10-CM Diagnosis Codes

Pair the procedure codes above with the appropriate ICD-10 diagnosis code to support medical necessity and avoid claim denials.

F10.10Alcohol use disorder, mild
F10.20Alcohol use disorder, moderate
F10.20Alcohol use disorder, severe
F10.230Alcohol dependence with withdrawal, uncomplicated
F10.231Alcohol dependence with withdrawal delirium (DTs)
F10.232Alcohol dependence with withdrawal with perceptual disturbance
F10.239Alcohol dependence with withdrawal, unspecified
F10.24Alcohol dependence with alcohol-induced mood disorder
F10.26Alcohol dependence with alcohol-induced persisting amnestic disorder
F10.27Alcohol dependence with alcohol-induced persisting dementia
F10.288Alcohol dependence with other alcohol-induced disorder
Z87.891Personal history of other specified conditions — alcohol use (aftercare)

How Rebound Vitamins Supports Your Medicaid Billing

Nutritional supplementation during detox (H0010, H0011) is a billable component of the residential detox day rate. Documenting Rebound Vitamins as part of your CIWA protocol strengthens the medical necessity narrative for higher-acuity codes (H0011 vs. H0010) and supports the clinical record for withdrawal management.

Facilities using Rebound as their standardized CIWA supplement can reference it in the treatment plan, nursing notes, and discharge summary — all of which support Medicaid audit defense and prior authorization renewals.

Clinical Questions

Frequently Asked Clinical Questions

Common questions from clinicians integrating Rebound Vitamins into their alcohol withdrawal protocols.

QDoes Rebound replace IV Thiamine?

No. High-dose IV Thiamine remains the standard of care when PO is not tolerated or when Wernicke's encephalopathy is suspected. Current EFNS guidelines (2010) and the Royal College of Physicians (Thomson et al., 2002) recommend 500 mg IV TID × 3 days for suspected Wernicke's — not the older 100 mg dose, which is insufficient for treatment. Rebound provides 100 mg oral Thiamine per tablet, appropriate for prophylaxis in patients tolerating PO. Always administer IV Thiamine 500 mg before any glucose-containing fluids in high-risk patients.

Thomson AD et al. Alcohol Alcohol. 2002;37(6):513–521.

QIs Rebound appropriate for all CIWA-Ar severity levels?

Rebound is appropriate at all severity levels where the patient is tolerating PO. For CIWA-Ar ≥ 20 or patients requiring ICU-level care, IV Thiamine 500 mg TID × 3 days should be given first per EFNS guidelines. Transition to Rebound Vitamins (100 mg oral Thiamine per tablet) as soon as oral intake is established for ongoing prophylaxis and nutritional repletion.

Saitz R et al. JAMA. 1994;272(7):519–523.

QWhat is the evidence basis for the dosing schedule?

The 5-day BID / 6-week daily schedule is designed around the UCSF symptom-triggered protocol window (Days 1–5 active monitoring) and the established recovery timeline for nutritional repletion in alcohol use disorder. Thiamine stores are typically repleted within 5–7 days of supplementation; continued daily dosing supports ongoing recovery.

Latt N, Dore G. Intern Med J. 2014;44(12):1167–1171.

QCan Rebound be prescribed at discharge?

Yes. Rebound is designed for both inpatient initiation and outpatient continuation. Prescribing or recommending Rebound at discharge ensures continuity of the nutritional support protocol through the 6-week recovery period.

QDoes Rebound interact with lorazepam or other benzodiazepines?

No clinically significant interactions are known between Rebound's nutritional components and benzodiazepines. Magnesium supplementation may support benzodiazepine efficacy by reducing neuromuscular excitability, but does not alter pharmacokinetics.

Elisaf M et al. J Trace Elem Med Biol. 1995;9(4):210–214.

General Practitioners & Primary Care Physicians

GPs Are the Front Line for AUD

Over 70% of patients with alcohol use disorder are seen in primary care before any specialist referral. GPs can screen, prescribe MAT, and manage long-term recovery — and bill appropriately for every step with E&M codes, SBIRT, and preventive care codes.

SBIRT at Every Visit

Bill 99408/G0396 alongside your E&M with modifier 25. No PA required for most commercial plans. AUDIT-C takes under 2 minutes.

In-Office MAT

With a DATA-waiver, prescribe buprenorphine (G2068) and naltrexone (G2070/J2315) in-office. Co-prescribe Rebound for ~$50 combined.

Preventive Visit Billing

Annual wellness visits (G0438/G0439) and preventive E&M codes (99385–99396) include AUD screening. Bill SBIRT separately with modifier 25.

View GP Billing Reference
Rehabilitation Facilities & Social Workers

Maximise Reimbursement at Every Level of Care

Residential H-codes, social worker CPT codes, group therapy, and MAT — all in one reference. Documenting CIWA-Ar scores and nutritional deficiencies can increase daily reimbursement by $200–$450 per patient by supporting H0011 over H0010.

H0011 vs H0010 — $200–$450/Day

CIWA-Ar >= 15 and nutritional deficiency codes (E51.2, E53.8) support H0011 (acute detox, $350–$800/day) over H0010 (subacute, $150–$350/day).

Social Worker Revenue

LCSWs bill 90832–90853 for individual and group therapy, plus 99408/H0049 for SBIRT. A full caseload generates $350–$700/week per clinician.

ASAM Criteria = PA Approval

All four major payers require ASAM criteria for residential PA requests. Document all six ASAM dimensions at admission to maximise approval rates.

Clinical Newsletter

Stay Current on CIWA Protocols & REBOUND Updates

Join clinicians and patients receiving evidence-based alcohol withdrawal resources, protocol updates, and REBOUND Vitamins news.

No spam. Unsubscribe anytime. Clinical content only.

References

  1. 1.

    Thomson AD, Cook CC, Touquet R, Henry JA; Royal College of Physicians, London. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and emergency department. Alcohol Alcohol. 2002;37(6):513–521.

  2. 2.

    Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Folate deficiency, methionine metabolism, and alcoholic liver disease. Alcohol. 2002;27(3):169–172.

  3. 3.

    Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol. 1995;9(4):210–214.

  4. 4.

    Leevy CM, Baker H. Vitamins and alcoholism. Am J Clin Nutr. 1968;21(11):1325–1328.

  5. 5.

    Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353–1357.

  6. 6.

    Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. JAMA. 1994;272(7):519–523.

  7. 7.

    Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med. 2002;162(10):1117–1121.

  8. 8.

    Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorder. Intern Med J. 2014;44(12):1167–1171.

  9. 9.

    Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–1795.

  10. 10.

    Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test. World Health Organization. 2001.

Medical Disclaimer: This page is intended as a clinical reference for licensed healthcare providers. Rebound Vitamins is a nutritional supplement, not a pharmaceutical product, and does not replace clinical judgment or institutional protocol. Always follow your institution's current approved protocol. IV Thiamine and IV Magnesium remain indicated when clinically required regardless of oral supplementation. — Wallace Peoples, C.E.O., W.Peoples Pharmaceuticals

Ready to Simplify Your
CIWA Supplement Orders?

Order Rebound Vitamins for your practice or review the full UCSF CIWA-Ar protocol with Rebound integration.

Replaces Thiamine, Folic Acid, Magnesium, and Multivitamin orders
Days 1–5: 1 tablet BID — active withdrawal repletion
Day 6 through 6 weeks: 1 tablet daily — maintenance
100mg Thiamine · 0.4mg Folate · Magnesium · Full B-complex
Designed for oral use during CIWA-Ar monitoring
For use under licensed clinical supervision